Clinical Study

Bxq-350- A Phase 1, Dose-Escalation, Open-Label, Safety And Pharmacokinetic, First In Human Study Of Bxq-350 Administered As A Single Agent By Intravenous Infusion In Adult Patients With Advanced Solid Tumors And Recurrent High-Grade Gliomas

Posted Date: Jul 26, 2017

  • Investigator: John Morris
  • Co-Investigator: Alison Kastl
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Drug

The purpose of this study is to test the safety of BXQ-350, an investigational drug, at different doses to find out what effects, if any, it has on people with cancer. An investigational drug means the drug is being tested and is not approved for sale by

Criteria:

To Be Eligible To Participate In This Study, Participants Must Have Advanced Solid Tumor Cancer Or A Specific Type Of Brain Cancer, Have Already Been Treated With Surgery, Radiation, And/Or Chemotherapy And The Cancer Is Now Growing.

Keywords:

Solid Tumors, Brain, Bxq-350, Cancer, Phase I

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.